Prognostic Markers of Disease Activity in Hodgkin's Disease
- 1 January 1998
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 29 (3-4) , 383-389
- https://doi.org/10.3109/10428199809068574
Abstract
The erythrocyte sedimentation rate (ESR), liver alkaline phosphatase (ALP), serum copper (Cu) and urinary nucleoside excretion (UNs) have been proposed as independent prognostic markers in Hodgkin's Disease (HD). However, their prognostic value has not satisfactorily been directly compared to recognised clinical prognostic factors. One hundred and sixty-eight patients with HD had the above markers performed prior to initial treatment. At a median follow-up of 10.9 yrs, the predicted 10 year relapse free survival (RFS) and overall survival (OS) for the entire cohort is 64% and 66%, respectively. In general, patients with elevated markers were significantly less likely to achieve CR, remain in CR and survive. However, multivariate analysis revealed this was due to the association of elevated markers with stage and constitutional symptoms. Following therapy, elevated markers were also correlated with evidence of clinically detectable disease. We conclude that although UNs, Cu, ALP and ESR reflect disease activity, they do not provide independent information beyond that of clinical assessment.Keywords
This publication has 11 references indexed in Scilit:
- Serum Trace Elements and Cu/Zn Ratio in Malignant Lymphomas in ChildrenJournal of Tropical Pediatrics, 1994
- A Numerical Prognostic Index for Clinical use in Identification of Poor-Risk Patients with Hodgkin's Disease at DiagnosisLeukemia & Lymphoma, 1992
- A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosisEuropean Journal of Cancer and Clinical Oncology, 1991
- Prognostic factors in Hodgkin's diseaseCancer Treatment Reviews, 1991
- Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.Journal of Clinical Oncology, 1990
- Reevaluation of alkaline phosphatase measurement during Hodgkin's disease by electrophoretic isoenzyme separationBritish Journal of Cancer, 1985
- Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkin's disease, non-Hodgkin's lymphoma, and nonmalignant lymphadenopathyCancer, 1985
- The clinical usefulness of serum copper determinations in Hodgkin's disease. A retrospective study of 241 patients from 1963–1973Cancer, 1976
- Transfer RNA and Transfer RNA Methylase Activity in Spleens of Patients With Hodgkin's Disease and Histiocytic LymphomaJNCI Journal of the National Cancer Institute, 1976
- Serum alkaline phosphatase at the onset of Hodgkin's diseaseCancer, 1970